Verona Pharma plc Verona Pharma To Present Clinical Trial Data Of Ensifentrine For Copd Maintenance Treatment At American Tho...
May 02 2019 - 7:00AM
UK Regulatory
TIDMVRP
LONDON, May 02, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP)
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on respiratory diseases, announces that it will present
data from its chronic obstructive pulmonary disease ("COPD") clinical
trial program with lead product candidate, ensifentrine (RPL554), at the
American Thoracic Society International Conference ("ATS") in Dallas, TX,
from May 17-22, 2019. The abstract reports post-hoc analyses of the
four-week placebo controlled dose-ranging study, with patients
sub-grouped by baseline reversibility of lung function measured pre- and
post-albuterol administration.
Ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes
phosphodiesterase 3 and 4 that has been shown to act both as an
anti-inflammatory and bronchodilator agent in a single compound. It is
currently in Phase 2b clinical trials for the maintenance treatment of
COPD and is planned to enter Phase 3 trials in 2020.
Details of the Company's poster presentation are listed below and the
abstract is now available to the public online at the American Thoracic
Society website (http://conference.thoracic.org/).
Thematic Poster Session (Abstract 3846, Poster 596): RPL554 (Dual PDE3/4
Enzyme Inhibitor): Baseline Airway Reversibility Impacts Immediate
Bronchodilation, in Contrast To Progressive Symptom Improvement
Session Title: COPD: Mechanism and Treatment (B64)
Date and Time: Monday, May 20, 2019; 9:15 AM - 4:15 PM CDT*
Location: Kay Bailey Hutchison Convention Center Dallas, Area D (Hall F,
Level 2)
Dave Singh, M.D., Professor of Clinical Pharmacology and Respiratory
Medicine, Medicines Evaluation Unit, University of Manchester, will be
available at the poster session from 11:15 AM -- 1:00 PM CDT.
About COPD
COPD is a progressive and life-threatening respiratory disease without a
cure. The World Health Organization estimates that it will become the
third leading cause of death worldwide by 2030. The condition damages
the airways and the lungs, leading to debilitating breathlessness that
has a devastating impact on performing basic daily activities such as
getting out of bed, showering, eating and walking. In the United States
alone, the 2010 total annual medical costs related to COPD were
estimated to be $32 billion and are projected to rise to $49 billion in
2020. About 800,000 US COPD patients on dual/triple inhaled therapy
(LAMA/LABA +/- ICS) remain uncontrolled, experiencing symptoms that
impair quality of life. These patients urgently need better treatments.
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs. Verona
Pharma's product candidate, ensifentrine (RPL554), is a first-in-class,
inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that
has been shown to act as both a bronchodilator and an anti-inflammatory
agent in a single compound. Ensifentrine is currently in Phase 2b
clinical development for the maintenance treatment of COPD and is
planned to enter Phase 3 trials for this indication in 2020. Verona
Pharma may also develop ensifentrine for the treatment of cystic
fibrosis and asthma.
In Phase 2 clinical studies in patients with moderate to severe COPD,
ensifentrine has shown significant and clinically meaningful
improvements in both lung function and COPD symptoms, including
breathlessness. In addition, ensifentrine has further improved lung
function and reduced lung volumes in patients taking standard short- and
long-acting bronchodilator therapy, including maximum bronchodilator
treatment with dual/triple therapy. Ensifentrine has been well tolerated
in clinical trials involving more than 800 people to date.
Forward-Looking Statements
This press release contains forward-looking statements. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including, but not limited to, statements regarding the value of trial
results presented at ATS, ensifentrine as a new complementary treatment
for patients with COPD, projected annual medical costs related to COPD,
the future clinical development and positioning of ensifentrine, and the
treatment potential for ensifentrine.
These forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from our expectations expressed or implied by
the forward-looking statements, including, but not limited to, the
following: our limited operating history; our need for additional
funding to complete development and commercialization of ensifentrine,
which may not be available and which may force us to delay, reduce or
eliminate our development or commercialization efforts; the reliance of
our business on the success of ensifentrine, our only product candidate
under development; economic, political, regulatory and other risks
involved with international operations; the lengthy and expensive
process of clinical drug development, which has an uncertain outcome;
serious adverse, undesirable or unacceptable side effects associated
with ensifentrine, which could adversely affect our ability to develop
or commercialize ensifentrine; potential delays in enrolling patients,
which could adversely affect our research and development efforts; we
may not be successful in developing ensifentrine for multiple
indications; our ability to obtain approval for and commercialize
ensifentrine in multiple major pharmaceutical markets; misconduct or
other improper activities by our employees, consultants, principal
investigators, and third-party service providers; material differences
between our "top-line" data and final data; our reliance on third
parties, including clinical investigators, manufacturers and suppliers,
and the risks related to these parties' ability to successfully develop
and commercialize ensifentrine; and lawsuits related to patents covering
ensifentrine and the potential for our patents to be found invalid or
unenforceable. These and other important factors under the caption "Risk
Factors" in our Annual Report on Form 20-F filed with the Securities and
Exchange Commission ("SEC") on March 19, 2019, and our other reports
filed with the SEC, could cause actual results to differ materially from
those indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management's
estimates as of the date of this press release. While we may elect to
update such forward-looking statements at some point in the future, we
disclaim any obligation to do so, even if subsequent events cause our
views to change. These forward-looking statements should not be relied
upon as representing our views as of any date subsequent to the date of
this press release.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Victoria Stewart, Director of Communications
N+1 Singer Tel: +44 (0)20 3283 4200
(Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate
Finance) Mia Gardener (Corporate Broking)
Optimum Strategic Communications
(European Media and Investor enquiries)
Mary Clark, Anne Marieke Ezendam, Hollie Vile Tel: +44 (0) 203 922 0891
verona@optimumcomms.com
Westwicke, an ICR Company
(US Media and Investor enquiries)
Darcie Robinson Tel: +1 203-919-7905
Darcie.Robinson@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
(END) Dow Jones Newswires
May 02, 2019 07:00 ET (11:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024